Goldman Sachs Group Inc. restated their buy rating on shares of Horizon Pharma Inc. (NASDAQ:HZNP) in a report published on Tuesday morning. Goldman Sachs Group Inc. currently has a $27.00 price target on the biopharmaceutical company’s stock.
Several other equities analysts have also issued reports on the company. BMO Capital Markets reissued an outperform rating and issued a $30.00 price target on shares of Horizon Pharma in a research note on Tuesday, September 13th. Morgan Stanley set a $24.00 price target on Horizon Pharma and gave the company a hold rating in a research note on Monday, September 12th. Mizuho boosted their price target on Horizon Pharma from $30.00 to $33.00 and gave the company a buy rating in a research note on Tuesday, September 13th. Brean Capital reissued a buy rating and issued a $32.00 price target on shares of Horizon Pharma in a research note on Monday, September 12th. Finally, Cowen and Company reissued an outperform rating and issued a $42.00 price target on shares of Horizon Pharma in a research note on Monday, September 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $30.00.
Horizon Pharma (NASDAQ:HZNP) opened at 17.77 on Tuesday. The stock’s 50 day moving average is $19.86 and its 200 day moving average is $17.66. The company’s market capitalization is $2.86 billion. Horizon Pharma has a 52 week low of $12.86 and a 52 week high of $23.70.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.12. The company had revenue of $257.40 million for the quarter, compared to analyst estimates of $235.43 million. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. The firm’s quarterly revenue was up 48.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.39 earnings per share. Analysts predict that Horizon Pharma will post $2.15 EPS for the current fiscal year.
In other Horizon Pharma news, EVP Jeffrey W. Sherman sold 2,900 shares of the business’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total value of $58,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.10% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Virginia Retirement System acquired a new position in Horizon Pharma during the first quarter valued at $282,000. Exane Derivatives acquired a new position in Horizon Pharma during the first quarter valued at $166,000. CQS Cayman LP acquired a new position in Horizon Pharma during the first quarter valued at $994,000. Pacad Investment Ltd. boosted its position in Horizon Pharma by 34.7% in the first quarter. Pacad Investment Ltd. now owns 67,867 shares of the biopharmaceutical company’s stock valued at $1,125,000 after buying an additional 17,484 shares in the last quarter. Finally, Algert Global LLC boosted its position in Horizon Pharma by 57.3% in the first quarter. Algert Global LLC now owns 20,872 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 7,602 shares in the last quarter. 85.25% of the stock is currently owned by institutional investors and hedge funds.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.